Novo Nordisk's obesity therapy Wegovy put in another strong sales performance ... pharmaceutical ingredients and finished injectable products – that will result in "continued periodic supply ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Novo Nordisk has such a blockbuster with Wegovy and Ozempic ... Novo Nordisk also manufactures and markets pharmaceutical products related to hormone therapy, hemophilia and growth disorders.

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

It includes Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic ... including aggregating multiple products that individually would not meet the requirements of the statute." ...

with key products like Ozempic and Wegovy patent-protected until 2031-2032. Despite high CapEx impacting free cash flow, future guidance suggests significant growth, making Novo Nordisk a cautious ...

And the deal will result in a hit of $1.26 billion this year from debt financing. Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, ...